Tetracyclines increase the survival of NSCLC patients treated with EGFR TKIs: a retrospective nationwide registry study

BACKGROUND: With the first and second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), clinical benefit and rash correlate together. EGFR TKI-induced rash can be alleviated with tetracyclines, but it is unknown whether the use of tetracyclines can increase the su...

Descripción completa

Detalles Bibliográficos
Autores principales: Alanen, Virve, Iivanainen, Sanna, Arffman, Martti, Koivunen, Jussi Pekka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7580060/
https://www.ncbi.nlm.nih.gov/pubmed/33087401
http://dx.doi.org/10.1136/esmoopen-2020-000864

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7580060/
https://www.ncbi.nlm.nih.gov/pubmed/33087401
http://dx.doi.org/10.1136/esmoopen-2020-000864

Ejemplares similares